Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06259929 | NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer(Neo-AGILE) | recruiting | Phase 2 | 51 | Fondazione OncotechOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06832904 | Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05) | recruiting | Phase 2 | 33 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Feb 18, 2025 |
| clinicaltrials |
| NCT06642545 | Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer | recruiting | Phase 2 | 40 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04356209 | Improving Theempowerment in Patients With Severe Breast Fibrosis Radio-induced Treated by Pravastatin : Benefit of e-PROs (Electronic " Patient Reported Outcome ") on Breast-related Quality of Life(PRAVACUR-02) | recruiting | Phase 2 | 105 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT06671262 | Neoadjuvant Toripalimab and Radiotherapy Treatment in N+ HR+ Breast Cancer(NEOTRIO-HR) | recruiting | Phase 2 | 74 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06819215 | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 188 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd.INDUSTRY | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06786026 | QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC | recruiting | Phase 2 | 60 | Fudan UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT05388149 | Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease | recruiting | Phase 2 | 15 | University Health Network, TorontoOTHER | 1 | Jan 31, 2025 | clinicaltrials |
| NCT06793553 | Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC(INDUCE) | recruiting | Phase 2 | 106 | Japan Breast Cancer Research GroupOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06793332 | BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC(BALISTA) | recruiting | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT05475678 | Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer | recruiting | Phase 2 | 369 | Zhenzhen LiuOTHER_GOV | 1 | Jan 23, 2025 | clinicaltrials |
| NCT06780748 | Photo-medicine-Guided Dual Approach for Reoperation of Sentinel Lymph Nodes in Locally Recurrent Breast Cancer Patients | recruiting | Phase 2 | 30 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06492005 | A Clinical Study of 9MW2821 (and PD-1 Inhibitor) in Locally Advanced or Metastatic Triple-Negative Breast Cancer | recruiting | Phase 2 | 160 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06276868 | Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer | recruiting | Phase 2 | 71 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 17, 2024 | clinicaltrials |
| NCT06636981 | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial | recruiting | Phase 2 | 129 | Fudan UniversityOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05974449 | Lactobacillus Vaginalis Capsules for Treatment of Vulvovaginal Atrophy in Young Breast Cancer Patients | recruiting | Phase 2 | 60 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06516289 | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | recruiting | Phase 2 | 130 | Fudan UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06401005 | SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC) | recruiting | Phase 2 | 51 | Hubei Cancer HospitalOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT05891561 | Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | recruiting | Phase 2 | 120 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT06538896 | Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06102824 | Organoid-based Functional Precision Therapy for Advanced Breast Cancer(ORIENTA) | recruiting | Phase 2 | 252 | Guangdong Provincial People's HospitalOTHER | 1 | Nov 25, 2024 | clinicaltrials |
| NCT06222879 | Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer | recruiting | Phase 1 / Phase 2 | 350 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 1 | Nov 25, 2024 | clinicaltrials |
| NCT03971045 | Pembrolizumab and Oral Metronomic Cyclophosphamide in Patients With Chest Wall Breast Cancer(PERICLES) | recruiting | Phase 2 | 46 | European Institute of OncologyOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06452706 | The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer | recruiting | Phase 2 | 42 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT04787042 | Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | recruiting | Phase 1 / Phase 2 | 316 | Simcha IL-18, Inc.INDUSTRY | 1 | Nov 15, 2024 | clinicaltrials |
| NCT06532812 | TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer(BAH249) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06677944 | Preoperative Partial Breast Irradiation in Early-Stage Breast Cancer | recruiting | Phase 2 | 47 | Yonsei UniversityOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05911958 | A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer | recruiting | Phase 2 | 66 | Henan Cancer HospitalOTHER_GOV | 1 | Nov 4, 2024 | clinicaltrials |
| NCT06656624 | Efficacy and Safety of Ribociclib Combined With AI Versus Physician&Amp;#39;s Choice of Chemotherapy Sequential Endocrine Therapy in ER Middle-low-expression/HER2-negative Advanced Breast Cancer (Rachel) | recruiting | Phase 2 | 190 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT06464913 | Randomized Phase II Trial: Chest Wall RT Omission After Prosthetic Reconstruction | recruiting | Phase 2 | 152 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05594095 | SNF Platform Study of HR+/ HER2-advanced Breast Cancer | recruiting | Phase 2 | 620 | Fudan UniversityOTHER | 1 | Oct 4, 2024 | clinicaltrials |
| NCT06185972 | Novel Magnetic Resonance Imaging-Guided Ultrasound-Stimulated Microbubble Radiation Treatment for Patients With Chest-Wall and Breast Cancer | recruiting | Phase 2 | 200 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT05019690 | Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | recruiting | Phase 1 / Phase 2 | 29 | Fujian Cancer HospitalOTHER_GOV | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05772390 | Partial Breast Re-irradiation in Women in Women with Locally Recurrent Breast Cancer Previously Treated with Conservative Surgery and Whole Breast Irradiation(PBReI) | recruiting | Phase 2 | 68 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06342037 | NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial(TONIC-3) | recruiting | Phase 2 | 60 | The Netherlands Cancer InstituteOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06176534 | Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial | recruiting | Phase 2 | 240 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 20, 2024 | clinicaltrials |
| NCT06508216 | A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer(COMPASS-TNBC) | recruiting | Phase 1 / Phase 2 | 50 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Jul 22, 2024 | clinicaltrials |
| NCT06236269 | HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan(ACROSS-TROP2) | recruiting | Phase 2 | 50 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT05635487 | A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients | recruiting | Phase 2 | 65 | Shengjing HospitalOTHER | 1 | Jul 5, 2024 | clinicaltrials |
| NCT03755739 | Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | recruiting | Phase 2 / Phase 3 | 200 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05187338 | Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT06472583 | Preoperative Immunotherapy Combined With Stereotactic Radiation Therapy Boost in the Treatment of HER2-negative Breast Cancer(BREAST-BOOSTER) | recruiting | Phase 2 | 78 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT05720260 | Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC | recruiting | Phase 2 | 42 | National Taiwan University HospitalOTHER | 1 | Jun 10, 2024 | clinicaltrials |
| NCT03815890 | Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO(BELLINI) | recruiting | Phase 2 | 80 | The Netherlands Cancer InstituteOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT06389006 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer | recruiting | Phase 2 | 79 | RemeGen Co., Ltd.INDUSTRY | 1 | May 23, 2024 | clinicaltrials |
| NCT06404697 | Boost Irradiation to the Supraclavicular Area Among High Risk cN3c Breast Cancer Patients | recruiting | Phase 2 | 24 | Ruijin HospitalOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06385990 | Utidelone (UTD1) Plus Capecitabine in Non-pCR TNBC After Neoadjuvant Therapy | recruiting | Phase 2 | 53 | Hunan Cancer HospitalOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06149130 | Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer | recruiting | Phase 2 | 82 | Tongji HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT06341894 | Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer | recruiting | Phase 2 | 1,163 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05861271 | Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer | recruiting | Phase 2 | 1,008 | Fudan UniversityOTHER | 1 | Mar 22, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Feb 18, 2025source: clinicaltrials